These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 16641342)

  • 1. Peripheral arteries: treatment with antibodies of platelet receptors and reteplase for thrombolysis--APART trial.
    Tepe G; Hopfenzitz C; Dietz K; Wiskirchen J; Heller S; Ouriel K; Ziemer G; Claussen CD; Duda SH
    Radiology; 2006 Jun; 239(3):892-900. PubMed ID: 16641342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reteplase monotherapy and reteplase/abciximab combination therapy in peripheral arterial occlusive disease: results from the RELAX trial.
    Ouriel K; Castaneda F; McNamara T; Swischuk J; Tepe G; Smith JJ; Clark J; Duda S
    J Vasc Interv Radiol; 2004 Mar; 15(3):229-38. PubMed ID: 15028807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial experience with the combination of reteplase and abciximab for thrombolytic therapy in peripheral arterial occlusive disease: a pilot study.
    Drescher P; Crain MR; Rilling WS
    J Vasc Interv Radiol; 2002 Jan; 13(1):37-43. PubMed ID: 11788692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reteplase with or without abciximab for peripheral arterial occlusions: efficacy and adverse events.
    Hull JE; Hull MK; Urso JA
    J Vasc Interv Radiol; 2004 Jun; 15(6):557-64. PubMed ID: 15178715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peripheral artery occlusion: treatment with abciximab plus urokinase versus with urokinase alone--a randomized pilot trial (the PROMPT Study). Platelet Receptor Antibodies in Order to Manage Peripheral Artery Thrombosis.
    Duda SH; Tepe G; Luz O; Ouriel K; Dietz K; Hahn U; Pereira P; Marsalek P; Ziemer G; Erley CM; Claussen CD
    Radiology; 2001 Dec; 221(3):689-96. PubMed ID: 11719664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clot lysis in a primate model of peripheral arterial occlusive disease with use of systemic or intraarterial reteplase: addition of abciximab results in improved vessel reperfusion.
    Nakada MT; Montgomery MO; Nedelman MA; Guerrero JL; Cohen SA; Barnathan ES; Jordan RE
    J Vasc Interv Radiol; 2004 Feb; 15(2 Pt 1):169-76. PubMed ID: 14963184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial.
    Lincoff AM; Califf RM; Van de Werf F; Willerson JT; White HD; Armstrong PW; Guetta V; Gibler WB; Hochman JS; Bode C; Vahanian A; Steg PG; Ardissino D; Savonitto S; Bar F; Sadowski Z; Betriu A; Booth JE; Wolski K; Waller M; Topol EJ;
    JAMA; 2002 Nov; 288(17):2130-5. PubMed ID: 12413372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial.
    Topol EJ;
    Lancet; 2001 Jun; 357(9272):1905-14. PubMed ID: 11425410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Catheter-directed thrombolytic therapy in peripheral artery occlusions: combining reteplase and abciximab.
    Drescher P; McGuckin J; Rilling WS; Crain MR
    AJR Am J Roentgenol; 2003 May; 180(5):1385-91. PubMed ID: 12704056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined glycoprotein IIb/IIIa receptor inhibition and low-dose fibrinolysis for peripheral arterial thrombosis.
    Rocha-Singh KJ; Trokey J
    Catheter Cardiovasc Interv; 2002 Apr; 55(4):457-60. PubMed ID: 11948891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group.
    Circulation; 2000 Jun; 101(24):2788-94. PubMed ID: 10859283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intra-arterial reteplase and intravenous abciximab in patients with acute ischemic stroke: an open-label, dose-ranging, phase I study.
    Qureshi AI; Harris-Lane P; Kirmani JF; Janjua N; Divani AA; Mohammad YM; Suarez JI; Montgomery MO
    Neurosurgery; 2006 Oct; 59(4):789-96; discussion 796-7. PubMed ID: 16915119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reteplase in the treatment of peripheral arterial and venous occlusions: a pilot study.
    Ouriel K; Katzen B; Mewissen M; Flick P; Clair DG; Benenati J; McNamara TO; Gibbens D
    J Vasc Interv Radiol; 2000; 11(7):849-54. PubMed ID: 10928520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early administration of reteplase plus abciximab vs abciximab alone in patients with acute myocardial infarction referred for percutaneous coronary intervention: a randomized controlled trial.
    Kastrati A; Mehilli J; Schlotterbeck K; Dotzer F; Dirschinger J; Schmitt C; Nekolla SG; Seyfarth M; Martinoff S; Markwardt C; Clermont G; Gerbig HW; Leiss J; Schwaiger M; Schömig A;
    JAMA; 2004 Feb; 291(8):947-54. PubMed ID: 14982910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic value of thrombolysis with adjunctive abciximab in patients with subacute peripheral arterial occlusion.
    Duda SH; Tepe G; Bala M; Luz O; Ziemer G; Ouriel K; Pusich B; Wiskirchen J; Claussen CD; Banz K
    Pharmacoeconomics; 2002; 20(3):203-13. PubMed ID: 11929350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events (FINESSE) trial.
    Ellis SG; Armstrong P; Betriu A; Brodie B; Herrmann H; Montalescot G; Neumann FJ; Smith JJ; Topol E;
    Am Heart J; 2004 Apr; 147(4):E16. PubMed ID: 15077099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombolytic and antiplatelet therapy in peripheral vascular disease with use of reteplase and/or abciximab. The SCVIR Consultants' Conference; May 22, 2000; Orlando, FL. Society for Cardiovascular and Interventional Radiology.
    Benenati J; Shlansky-Goldberg R; Meglin A; Seidl E;
    J Vasc Interv Radiol; 2001 Jul; 12(7):795-805. PubMed ID: 11435535
    [No Abstract]   [Full Text] [Related]  

  • 18. Outcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: lessons from the GUSTO V trial.
    Gurm HS; Lincoff AM; Lee D; Tang WH; Jia G; Booth JE; Califf RM; Ohman EM; Van de Werf F; Armstrong PW; Guetta V; Wilcox R; Topol EJ;
    J Am Coll Cardiol; 2004 Feb; 43(4):542-8. PubMed ID: 14975461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of abciximab on prothrombin activation and thrombin generation in patients with acute myocardial infarction also receiving reteplase.
    Merlini PA; Repetto A; Andreoli AM; Ricci S; Lombardi A; Finardi A; Dipasquale G; Lamponi M; Mannucci PM; Ardissino D
    Am J Cardiol; 2004 Jan; 93(2):195-8. PubMed ID: 14715345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Local intraarterial urokinase thrombolysis of acute ischemic stroke with or without intravenous abciximab: a pilot study.
    Lee DH; Jo KD; Kim HG; Choi SJ; Jung SM; Ryu DS; Park MS
    J Vasc Interv Radiol; 2002 Aug; 13(8):769-74. PubMed ID: 12171979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.